Novelix Pharmaceuticals Limited - Company Profile

It is a pharma public limited company based in Himayathnagar, Telangana, India, established in 1994.
1994 Himayathnagar, Telangana, India Active
Last Updated:
Access Report
About Novelix Pharmaceuticals Limited

Novelix Pharmaceuticals Limited, a active public limited company, was established on 13 December 1994 in Himayathnagar, Telangana, India. Engaging in pharmaceutical retailers & distributors within the financial and insurance service sector, it holds CIN: L67120TG1994PLC018956. Registered under ROC Roc Hyderabad. it is listed on BSE: 536565. It has an authorized capital of ₹30.00 Cr and a paid-up capital of ₹16.14 Cr.

Formerly known as Trimurthi Drugs & Pharmaceuticals Limited, Trimurthi Limited. It upholds a compliant status. In 2023, it reported revenue of ₹1.92 Cr and a net worth of ₹7.20 Cr. Its leadership includes Jivamohan Divakar Valluri (Director), Gnana Prakash Gattu (Director), Nishita Kalantri (Company Secretary). Past directors included Sowjanya Sarapu, Vijaykumar Taori, Jivamohan Divakar Valluri. It holds ₹8.50 M open charges and no settled loans. Its latest AGM occurred on 27 September 2024, with the balance sheet filed on 31 March 2024. It is based at Flat # 610, 6Th Floor, H.No.3-6-237/610, Lingapur La Builders ( Also Known As Amrutha Estate), Himayathnagar, Telangana, 500029.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    L67120TG1994PLC018956

  • Registration Number

    018956

  • Incorporation Date

    13 December 1994

  • Authorized Capital

    ₹30.00 Cr

  • Paid-Up Capital

    ₹16.14 Cr

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Listed (BSE: 536565)

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 30.00 Cr
  • Paid Up Capital ₹ 16.14 Cr
  • Company Age 31 Year, 2 Months
  • Last Filing with ROC 31 Mar 2024
  • Open Charges ₹ 8.50 M
  • Revenue Growth **** 37.67%
  • Profit Growth **** 96.16%
  • Ebitda **** 74.68%
  • Net Worth -0.66%
  • Total Assets **** 0.08%
Company report

Novelix Pharmaceuticals Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Novelix Pharmaceuticals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Novelix Pharmaceuticals Limited?
Current Directors
Name Designation Appointment Date Status
Jivamohan Divakar Valluri Director 12 Apr 2025 Current
Gnana Prakash Gattu Director 14 Aug 2025 Current
Nishita Kalantri Company Secretary 01 Apr 2019 Current
Janardhan Das Kabra Director 02 Sep 2024 Current
Venkateshwarlu Pulluru Whole-Time Director 02 Sep 2024 Current
Lakshman Samala Director 12 Feb 2025 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 12 Feb 2022 Past
Pramod Abcsdd Director 28 Sep 2013 Past
Pramod Abcsdd Additional Director 08 May 2025 Past
Pramod Abcsdd Additional Director 26 Sep 2024 Past
Pramod Abcsdd Additional Director 19 Aug 2022 Past
Pramod Abcsdd Director 05 Nov 2016 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Novelix Pharmaceuticals.

Novelix Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 37.67% increase. The company also saw a substantial improvement in profitability, with a 96.16% increase in profit. The company's net worth dipped by a decrease of 0.66%.

Novelix Pharmaceuticals revenue growth over time
Novelix Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 37.67%
*******
*******
*******
*******
Revenue from Operations
*******
 66.58%
*******
*******
*******
*******
Total Assets
*******
 0.08%
*******
*******
*******
*******
Profit or Loss
*******
 96.16%
*******
*******
*******
*******
Net Worth
*******
 -0.66%
*******
*******
*******
*******
EBITDA
*******
 74.68%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Novelix Pharmaceuticals?

In 2023, Novelix Pharmaceuticals had a promoter holding of 66.92% and a public holding of 33.08%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹8,500,000.00

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions
  • Canara Bank : 0.85 Cr
Latest Charge Details
Date Lender Amount Status
07 Nov 2025 Canara Bank ₹8.50 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Novelix Pharmaceuticals?

Unlock and access historical data on people associated with Novelix Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Novelix Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novelix Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Novelix Pharmaceuticals
Recent Activity within the Organization
  • Charges

    The activity A charge with Canara Bank amounted to Rs. 0.85 Cr with Charge ID 101192851 was registered on 07 Nov 2025. was completed.

  • Director Appointment

    Progress on Sridevi Belide was appointed as a Director was appointed as a Director on 23 Oct 2025 & has been associated with this company since 4 months 9 days . was documented.

  • Director Appointment

    The activity Gnana Prakash Gattu was appointed as a Director was appointed as a Director on 14 Aug 2025 & has been associated with this company since 6 months 18 days . was completed.

  • Director Appointment

    The activity Mayuri Baidya was appointed as a Director was appointed as a Director on 14 Aug 2025 & has been associated with this company since 6 months 18 days . was completed.

  • Director Appointment

    Jivamohan Divakar Valluri was appointed as a Director was appointed as a Director on 12 Apr 2025 & has been associated with this company since 10 months 19 days . was recorded as a recent event.

  • Director Appointment

    The activity Bhoomika Choudhary was appointed as a Cfo was appointed as a Cfo on 22 Feb 2025 & has been associated with this company since 1 year 7 days . was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Novelix Pharmaceuticals Limited?

The CIN of Novelix Pharmaceuticals Limited is L67120TG1994PLC018956.

Where is Novelix Pharmaceuticals Limited headquartered?

Novelix Pharmaceuticals Limited is headquartered at Flat # 610, 6Th Floor, H.No.3-6-237/610, Lingapur La Builders ( Also Known As Amrutha Estate), Himayathnagar, Telangana, 500029.

When was Novelix Pharmaceuticals Limited incorporated?

Novelix Pharmaceuticals Limited was incorporated on 13 December 1994.

Who are the current directors of Novelix Pharmaceuticals Limited?

The current directors of Novelix Pharmaceuticals Limited are

What is the primary industry of Novelix Pharmaceuticals Limited?

The primary industry of Novelix Pharmaceuticals Limited is Financial And Insurance Service.

Is Novelix Pharmaceuticals Limited a listed company?

Novelix Pharmaceuticals Limited is listed. It is listed on BSE: 536565.

What is the capital structure of Novelix Pharmaceuticals Limited?

The authorized capital of Novelix Pharmaceuticals Limited is ₹30.00 Cr, and the paid-up capital is ₹16.14 Cr.

What is the compliance status of Novelix Pharmaceuticals Limited?

The compliance status of Novelix Pharmaceuticals Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available